Liz Helms, CEO of the Chronic Care Policy Alliance (CCPA), issued the following statement on Most Favored Nation pricing:
“Most Favored Nation (MFN) pricing is not a patient-centered solution and will likely fail to produce sustainable savings. Importing international pricing benchmarks risks importing foreign health technology assessment tools, such as quality-adjusted life year (QALY) thresholds, an unethical process that explicitly devalues the lives of older adults, people with disabilities, and those with chronic illness. These approaches threaten innovation and restrict access to lifesaving therapies.
“We continue to urge for reforms and oversight of Pharmacy Benefit Managers (PBMs), the real middlemen who drive up costs in the system. These policies put patients first by bringing down costs for medications and therapies. Put simply, policymakers should reject blunt, coercive pricing schemes and instead focus on durable solutions that protect patients, preserve innovation, and address the true drivers of drug costs,” concluded Helms.